| 摘要 |
The present invention relates to a progranulin induced receptor like gene during osteoclastogenesis (PIRO) which is a novel biomarker for osteoclast fusion. More particularly, the present invention relates to a composition which includes, as an active ingredient, an inhibitor against PIRO to prevent or treat osteoporosis and has been newly developed as a factor involved in osteoclast fusion causing osteoporosis, or for inducing osteoclast fusion by comprising the PIRO as an active ingredient. According to the present invention, PIRO performs an important role in the RANK signal transduction system and is a late phase factor of osteoclast fusion and bone resorption and a direct inducer gene of progranulin. Therefore, PIRO may be useful as a biomarker in the development of a novel agent for preventing or treating osteoporosis or the diagnosis of osteoporosis, or the determining of therapeutic results, or prognoses. When the PIRO inhibitor is used, osteoporosis may be effectively prevented or treated. |
